Literature DB >> 6246531

Two distinct loci confer resistance to acycloguanosine in herpes simplex virus type 1.

D M Coen, P A Schaffer.   

Abstract

Two distinct loci that confer resistance to acycloguanosine (acyclo-Guo) in herpes simplex virus types 1 have been identified. The first locus is the gene for the virus-specific thymidine kinase (TK). Mutations that decrease TK activity also render the virus resistant to acyclo-Guo, and the level of resistance corresponds to the decrease in TK activity. acyclo-Guo resistance due to defective TK expression is recessive to the wild-type phenotype, acyclo-Guo-sensitive (ACGs). We term this locus ACGr-TK. The second locus is defined by the properties of a mutant, PAAr5, which is resistant to acyclo-Guo and to phosphonoacetic acid (PAA) yet exhibits wild-type TK activity. The acyclo-Guo-resistant locus in PAAr5 is separable from ACGr-TK mutations by recombination. Moreover, PAAr5 and ACGr-TK mutants can complement each other, producing drug-sensitive gene products which result in growth inhibition in the presence of acyclo-Guo. The acyclo-Guo resistance conferred by PAAr5 behaves as though it were codominant with the wild-type phenotype. This second acyclo-Guo-resistance locus is closely linked to the mutation specifying resistance to PAA. Resistance to PAA is thought to result from mutations in the gene for viral DNA polymerase. Thus, the close linkage of the ACGr and PAAr loci suggest that resistance to both drugs is specified by a mutant DNA polymerase. We term this second locus ACGr-PAA.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6246531      PMCID: PMC348694          DOI: 10.1073/pnas.77.4.2265

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  20 in total

1.  Identification of the herpes simplex virus DNA polymerase gene.

Authors:  D J Purifoy; R B Lewis; K L Powell
Journal:  Nature       Date:  1977-10-13       Impact factor: 49.962

2.  Cell-free synthesis of herpes simplex virus-coded pyrimidine deoxyribonucleoside kinase enzyme.

Authors:  C M Preston
Journal:  J Virol       Date:  1977-09       Impact factor: 5.103

3.  Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine.

Authors:  G B Elion; P A Furman; J A Fyfe; P de Miranda; L Beauchamp; H J Schaeffer
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

4.  Recombination between temperature-sensitive mutants of herpes simplex virus type 1.

Authors:  P A Schaffer; M J Tevethia; M Benyesh-Melnick
Journal:  Virology       Date:  1974-03       Impact factor: 3.616

5.  Spectrum of human cytomegalovirus complement-fixing antigens.

Authors:  G R Dreesman; M Benyesh-Melnick
Journal:  J Immunol       Date:  1967-12       Impact factor: 5.422

6.  Mutants of herpes simplex virus types 1 and 2 that are resistant to phosphonoacetic acid induce altered DNA polymerase activities in infected cells.

Authors:  J Hay; J H Subak-Sharpe
Journal:  J Gen Virol       Date:  1976-04       Impact factor: 3.891

7.  Mode of inhibition of herpes simplex virus DNA polymerase by phosphonoacetate.

Authors:  J C Mao; E E Robishaw
Journal:  Biochemistry       Date:  1975-12-16       Impact factor: 3.162

8.  Mechanism of phosphonoacetate inhibition of herpesvirus-induced DNA polymerase.

Authors:  S S Leinbach; J M Reno; L F Lee; A F Isbell; J A Boezi
Journal:  Biochemistry       Date:  1976-01-27       Impact factor: 3.162

9.  Genetics of resistance to phosphonoacetic acid in strain KOS of herpes simplex virus type 1.

Authors:  J T Jofre; P A Schaffer; D S Parris
Journal:  J Virol       Date:  1977-09       Impact factor: 5.103

10.  Herpes simplex virus resistance and sensitivity to phosphonoacetic acid.

Authors:  R W Honess; D H Watson
Journal:  J Virol       Date:  1977-02       Impact factor: 5.103

View more
  89 in total

1.  Herpes simplex virus ribonucleotide reductase mutants are hypersensitive to acyclovir.

Authors:  D M Coen; D J Goldstein; S K Weller
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

Review 2.  Slipping and sliding: frameshift mutations in herpes simplex virus thymidine kinase and drug-resistance.

Authors:  Anthony Griffiths
Journal:  Drug Resist Updat       Date:  2011-09-22       Impact factor: 18.500

3.  Priscilla Schaffer (1941-2009): a stalwart herpesvirologist.

Authors:  Donald Coen
Journal:  J Virol       Date:  2010-04-28       Impact factor: 5.103

Review 4.  Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management.

Authors:  Jocelyne Piret; Guy Boivin
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

5.  Manzamine A as a novel inhibitor of herpes simplex virus type-1 replication in cultured corneal cells.

Authors:  Jayavardhana R Palem; Gautam R Bedadala; Khalid A El Sayed; Shao-chung V Hsia
Journal:  Planta Med       Date:  2010-07-19       Impact factor: 3.352

6.  Clinical isolate of herpes simplex virus type 2 that induces a thymidine kinase with altered substrate specificity.

Authors:  M N Ellis; P M Keller; J A Fyfe; J L Martin; J F Rooney; S E Straus; S N Lehrman; D W Barry
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

7.  Nucleotide sequence changes in thymidine kinase gene of herpes simplex virus type 2 clones from an isolate of a patient treated with acyclovir.

Authors:  S Kit; M Sheppard; H Ichimura; S Nusinoff-Lehrman; M N Ellis; J A Fyfe; H Otsuka
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191

Review 8.  Prophylaxis for genital herpes. Should it be used routinely?

Authors:  A Mindel
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

Review 9.  Persistent herpes simplex virus infection and mechanisms of virus drug resistance.

Authors:  H J Field
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-08       Impact factor: 3.267

10.  In vitro mutagenesis of the herpes simplex virus type 1 DNA polymerase gene results in altered drug sensitivity of the enzyme.

Authors:  J T Matthews; R D Carroll; J T Stevens; M L Haffey
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.